Unavailable
Unavailable
Save time and jump to the most important pieces.
SC 13G/A - Trinity Place Holdings Inc. (0000724742) (Subject)
SC 13D/A - Trinity Place Holdings Inc. (0000724742) (Subject)
SC 13D/A - Trinity Place Holdings Inc. (0000724742) (Subject)
10-Q - Trinity Place Holdings Inc. (0000724742) (Filer)
10-Q - Trinity Place Holdings Inc. (0000724742) (Filer)
8-K - Trinity Place Holdings Inc. (0000724742) (Filer)
Trinity Place Holdings Inc. (NYSE:TPHS) (the "Company") announced that on February 21, 2024, the NYSE American notified the Company that it had reviewed the plan of compliance (the "Plan") that the Company submitted to the NYSE American and determined to accept the Plan and grant a cure period through May 29, 2025. As previously disclosed, on November 29, 2023, the Company received a deficiency letter from the NYSE American indicating that the Company was not in compliance with the NYSE American's continuing listing standards set forth in Sections 1003(a)(i) and (ii) of the NYSE Company Guide since it reported stockholders' deficit of $(1.2) million as of September 30, 2023 and losses from
Trinity Place Holdings Inc. (NYSE:TPHS) (the "Company") announced that on February 14, 2024 the Company closed its previously announced recapitalization transactions. In connection with these transactions, the maturity date of each of the mortgage loan agreement and mezzanine loan agreement for the 77 Greenwich property was extended to October 23, 2025 with an option to extend for an additional year. At the closing, the lender under the Company's corporate credit facility purchased 25,112,245 shares of common stock of the Company and the maturity date of the Company's corporate credit facility was extended to June 30, 2026. In addition, an affiliate of the lender acquired a 5% interest in a
Trinity Place Holdings Inc. (NYSE:TPHS) (the "Company") announced that, effective as of January 5, 2024, the Company had entered into a stock purchase agreement with the lender under its corporate credit facility and an affiliate of such lender (the "Investor"), pursuant to which the Investor will be issued 25,112,245 shares of common stock of the Company for a purchase price of $0.30 per share in accordance with the terms and conditions of the stock purchase agreement. At the closing of the transactions contemplated by the stock purchase agreement, the Company and the Investor will enter into a joint venture agreement, pursuant to which the joint venture will be appointed the initial manag
4 - Trinity Place Holdings Inc. (0000724742) (Issuer)
4 - Trinity Place Holdings Inc. (0000724742) (Issuer)
4 - Trinity Place Holdings Inc. (0000724742) (Issuer)
Shares of Mainz Biomed N.V. (NASDAQ:MYNZ) rose sharply in today's pre-market trading after the company announced submission for the FDA Breakthrough Device Designation for its next generation CRC screening test. Mainz Biomed shares jumped 16% to $0.5534 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Pineapple Energy Inc. (NASDAQ:PEGY) rose 85% to $2.22 in pre-market trading. Pineapple Energy engaged Conduit Capital to provide structural internal support, staffing, and assistance with capital raising activities. Zapp Electric Vehicles Group Limited (NASDAQ:ZAPP) shares rose 43.5% to $13.26 in pre-market trading after gaining 127% on Mon
Shares of Kaival Brands Innovations Group, Inc. (NASDAQ:KAVL) fell sharply during Friday's session after the company announced pricing of $6.0 million public offering. Kaival Brands priced its 3,921,500 unit offering at $15.3 per unit. Kaival Brands Innovations Group shares dipped 47% to $1.52 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers American Rebel Holdings, Inc. (NASDAQ:AREB) shares jumped 161% to $0.8048 after the company signed a Connecticut distribution agreement with Dichello Distributors. Sharecare, Inc. (NASDAQ:SHCR) jumped 74% to $1.35 after the company agreed to be acquired by Altaris affiliate for $1.43 per share in cash.
Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rose sharply in today's pre-market trading after the company announced expanded US FDA approval of ELEVIDYS to Duchenne Muscular Dystrophy patients ages 4 and above. Sarepta Therapeutics shares climbed 35.2% to $166.96 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Spectaire Holdings Inc (NASDAQ:SPEC) rose 110% to $0.7140 in pre-market trading after the company announced a purchase order and delivery of its advanced AireCore units to American Ag Energy. DermTech, Inc. (NASDAQ:DMTK) gained 105.5% to $0.2423 in pre-market trading after declining 19% on Thursday. DermTech recently filed f